You are here:
Calquence
Mantle cell lymphoma (MCL), 1L.
No estimate possible yet
13,923,396.00
Clinical trials
Acalabrutinib
Hematology
Indication extension
Aggressive non-Hodgkin’s lymphoma
AstraZeneca
Tyrosine kinase inhibitor
Oral
Tablet
Intermural (MSZ)
Centralised (EMA)
Normal trajectory
No
2024
2025
Yes
Indiening gepland in de tweede helft van 2024 en registratie gepland in de tweede helft van 2025
Rituximab-CHOP of BR
continuous
2 times a day
100mg
NCT02972840 (ECHO)
< 222
Market share is generally not included unless otherwise stated.
IKNL
Incidentie betreft in totaal 222 patiënten in 2020 voor Mantle Cell Lymphoma (MCL).
62,718.00
Z-Index 2022; ZIN pakketadvies acalabrutinib 2022
De apotheekinkoopprijs (AIP) van acalabrutinib is €4.811,27 voor 56 tabletten met 100 gram acalabrutinib (Z-Index). De aanbevolen dagelijkse dosering is 200mg (2 capsules) waarmee de kosten op €171,83 per dag komen. De kosten voor behandeling met acalabrutinib komen daarmee op €62.718 per jaar.
This amount gives an indication of the total cost. It is the result of the average expected patient volume times the average cost per patient. both per year.
There is currently nothing known about off label use.
Zie andere indicatie op de Horizonscan Geneesmiddelen. Daarnaast ook in fase 3: Relapsed or refractory chronic lymphocytic leukaemia (CLL) in high-risk patients
SPS UK
There is currently no futher information available.
Understanding of expected market entry of innovative medicines